Evidence map›Paper›PMID 40906442›Full record

ArticleAmerican journal of reproductive immunology (New York, N.Y. : 1989)2025

Chemokines and Their Association With Symptom Severity in Women With Endometriosis.

Anton Sommar, Pinar Yalcin Bahat, Ipek Yildiz Özaydin, Eray Metin Güler, Marie Bixo, Torbjörn Bäckström, Engin Oral, Sahruh Turkmen

Abstract read
In one paragraph

Article in American journal of reproductive immunology (New York, N.Y. : 1989), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Chemokines and Their Association With Symptom Severity in Women With Endometriosis.American journal of reproductive immunology (New York, N.Y. : 1989) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Anton SommarDepartment of Clinical Sciences, Obstetrics and Gynecology, Umeå University, Umeå, Sweden.
Pinar Yalcin BahatDepartment of Obstetrics and Gynecology, Istanbul Kanui Sultan Suleyman Training and Research Hospital, Istanbul, Turkey.
Ipek Yildiz ÖzaydinDepartment of Pathology, Istanbul Kanui Sultan Suleyman Training and Research Hospital, Istanbul, Turkey.
Eray Metin GülerDepartment of Medical Biochemistry, Hamidiye Faculty of Medicine, University of Health Sciences Turkey, Istanbul, Turkey.
Marie BixoDepartment of Clinical Sciences, Obstetrics and Gynecology, Umeå University, Umeå, Sweden.
Torbjörn BäckströmDepartment of Clinical Sciences, Obstetrics and Gynecology, Umeå University, Umeå, Sweden.
Engin OralMedical Faculty, Department of Obstetrics and Gynecology, Biruni University, Istanbul, Turkey.
Sahruh TurkmenDepartment of Clinical Sciences, Obstetrics and Gynecology, Umeå University, Umeå, Sweden.

Funding

Department of Research and Development (FOU)Region Västernorrland
6 · The paper itself

Abstract

problemVarious chemokines have been linked to endometriosis. Notably, chemokines such as CCL2, CXCL8, and CXCL1 have also been shown to promote nociception. In this study, we investigated whether increased serum concentrations and endometrial expression of chemokines (specifically CCL2, CXCL8, and CXCL1) are associated with heightened severity of pain symptoms in women with endometriosis. METHOD OF STUDY: The study included women with endometriosis (with [n = 27] and without [n = 24] hormonal treatment) as well as healthy controls (n = 22). All participants underwent blood sampling and an endometrial biopsy during the secretory phase of the menstrual cycle. Symptom severity in the patient group was assessed using the pain dimension of the Endometriosis Health Profile 30 (EHP-30) and a visual analog scale (VAS) for pain.

resultsSerum levels of CCL2 and CXCL1, as well as endometrial expression of CXCL8, were lower in women with endometriosis compared to controls. Furthermore, increased serum levels of CCL2, CXCL8, and CXCL1 were associated with higher EHP-30 pain domain scores in women with endometriosis. Similarly, elevated endometrial expression of CXCL8 and CXCL1 correlated with higher VAS scores. Notably, when the patient group was stratified based on ongoing hormonal treatment, CXCL1 emerged as the most promising target, with both increased serum concentration and endometrial expression consistently being associated with greater symptom severity.

conclusionsOur results suggest that chemokines, particularly CXCL1, are associated with greater pain severity and reduced quality of life in women with endometriosis. However, these correlations do not establish causality and should be interpreted with caution.

Indexed as

Chemokine CCL2Chemokine CXCL1ChemokinesEndometriosisEndometriumInterleukin-8PainAdultFemaleHumansSeverity of Illness IndexYoung AdultChemokine CCL2Chemokine CXCL1ChemokinesCXCL1 protein, humanCXCL8 protein, humanInterleukin-8CCL2chemokineCXCL1CXCL8endometriosispain

Identifiers

PMID40906442
PMCPMC12410295

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.